Archives
-
NF 449 as a Selective P2X1 Receptor Antagonist
2026-10-03
Rettinger and colleagues used recombinant rat P2X receptors to show that NF 449 is exceptionally potent at receptors containing the P2X1 subunit, while being far less active at several related receptor assemblies. The study established a receptor-level pharmacological tool for separating P2X1-mediated ATP signaling from broader purinergic responses, while also defining important limits on how its findings should be applied to native tissues.
-
Dual-Readout mRNA for Translational Insight
2026-10-02
A mechanistic and strategic guide to using Cap1-capped, 5-moUTP-modified, Cy5-labeled firefly luciferase mRNA to separate delivery, intracellular trafficking, and productive translation in translational research.
-
Deferasirox Fe3+ Chelate: Lab Workflow
2026-10-01
Build reproducible iron-overload assays around a defined ferric chelate rather than relying on poorly controlled aqueous dosing. This workflow combines DMSO-compatible preparation, orthogonal iron and toxicity readouts, and translational guardrails for beta-thalassemia and chronic anemia research.
-
Haloprogin: Findings from a 1970 Antifungal Study
2026-10-01
The 1970 study positioned Haloprogin as a topical antifungal with dermatophyte activity comparable to tolnaftate, while revealing additional activity against Candida species and selected Gram-positive bacteria. Its combined serial-dilution, fungicidal, serum-effect, and guinea pig infection experiments provide a useful framework for interpreting spectrum, formulation, and translational limitations.
-
Primidone and CYP19: Evidence from an Antiepileptic Study
2026-09-30
The reference study systematically examined whether 12 antiepileptic drugs inhibit human aromatase (CYP19), linking in vitro enzyme activity to possible steroid-hormone effects. Primidone, also known as Mysoline, showed no detectable CYP19 inhibition in the tested system, whereas several other drugs inhibited aromatase and selected combinations produced additive effects.
-
2'3'-cGAMP: Reframing STING Translation
2026-09-30
2'3'-cGAMP is more than a canonical STING agonist: it is a precision probe for separating cGAS activation, cGAMP transport, and STING competence. This article translates recent evidence on ABCC10-mediated cGAMP efflux and radiotherapy resistance into an experimental strategy for immunotherapy and cancer researchers.
-
PX-478 2HCl: Reliable HIF-1α Assays
2026-09-29
A scenario-driven guide to using PX-478 2HCl (SKU B6004) in viability, proliferation, cytotoxicity, hypoxia, and radiosensitization workflows. It connects product parameters with controls, interpretation, cross-model limitations, and practical vendor-selection criteria.
-
MVC Activates RhoA/ROCK1/MLC2 to Disrupt Tight Junctions
2026-09-29
Ren and colleagues identify a previously uncharacterized entry mechanism in which MVC VP2 interacts with ROCK1 and activates the RhoA/ROCK1/MLC2 axis, remodeling tight junctions in WRD cells. The study connects actomyosin contraction, Occludin redistribution, and viral replication, providing a mechanistic basis for investigating host-directed anti-MVC strategies.
-
Azathramycin A in TB Ribosome Research
2026-09-28
Azathramycin A supports a practical bridge between cell-free ribosome-binding studies and Mycobacterium tuberculosis infection model research. This workflow-focused guide covers solvent handling, orthogonal mechanism-of-action assays, degradation monitoring, and troubleshooting for reproducible antibacterial agent for tuberculosis research.
-
HyperPFU™ high-fidelity DNA polymerase: PCR Guide
2026-09-28
HyperPFU™ high-fidelity DNA polymerase is intended for accurate amplification of long, GC-rich, or otherwise difficult DNA templates, with blunt-ended products suited to cloning and sequencing workflows. It is not the right choice when a PCR product must carry 3′-A overhangs or sticky ends; plan to add the required end structure using a separate, validated step.
-
Primary Antibody Dilution Buffer for PCNSL Assays
2026-09-27
Translate single-cell findings on SLC2A5-mediated fructose metabolism into practical protein-localization experiments with a buffer designed for primary-antibody preparation. This workflow highlights how to optimize staining in challenging CNS lymphoma samples—while keeping immunostaining evidence distinct from metabolic-function claims.
-
Suhuang Suppresses ER Stress–Linked NLRP3 in CVA
2026-09-26
In an ovalbumin-induced cough variant asthma model, Suhuang antitussive capsule improved pulmonary dysfunction while reducing endoplasmic reticulum stress and NLRP3 inflammasome activation. The study’s pharmacological perturbations support a role for ER stress and a TXNIP–RIP1/RIP3–Drp1 axis in connecting cellular stress to inflammatory signaling, although the findings remain preclinical.
-
Baicalein Workflows for Cancer and Inflammation Studies
2026-09-25
Use Baicalein to probe 12-LOX-linked arachidonic acid metabolism, inflammatory signaling, and cancer-cell responses with dose-controlled, vehicle-matched workflows. A neurotoxicity study offers a useful model for separating protective effects from anticancer activity—but its findings concern formononetin, not Baicalein.
-
Stromal Remodeling Nanomedicine for Pancreatic Cancer
2026-09-25
This study reports an acid-responsive, sequential-release nanomedicine designed to remodel pancreatic tumor stroma before delivering gemcitabine. In a mouse model, the combined formulation was associated with marked tumor regression, supporting further investigation of stromal normalization as a way to improve drug access while leaving clinical efficacy unestablished.
-
Deferasirox Fe3+ Chelate in Iron Overload Research
2026-09-24
Build iron-handling experiments around the ferric complex itself—not assumptions about the unbound oral chelator. This guide translates clinical context into controlled workflows, solvent-aware handling, and practical checks for beta-thalassemia and chronic anemia models.